<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04277663</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI310A301</org_study_id>
    <nct_id>NCT04277663</nct_id>
  </id_info>
  <brief_title>The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery</brief_title>
  <official_title>A Phase 3, Open-label, Multicenter Study, IBI310 in Combination With IBI308 and IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III randomized, control, multi-center study of recombinant humanized
      anti-PD-1 mAb in combination with CTLA4 mAb for injection compared to high-Dose interferon in
      patients with acral melanoma that has been removed by surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2020</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">April 18, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence-free survival rate</measure>
    <time_frame>up to 5 years after enrollment</time_frame>
    <description>to evaluate the Recurrence free survival (RFS) of the patients with acral melanoma treated by IBI310 in Combination With IBI308 and high-Dose interferon</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 5 years after enrollment</time_frame>
    <description>to evaluate the Overall survival (OS) of the patients with acral melanoma treated by IBI310 in Combination With IBI308 and high-Dose interferon</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Acral Melanoma That Has Been Removed by Surgery</condition>
  <arm_group>
    <arm_group_label>IBI310 + IBI308</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be treated with IBI310 in combination with IBI308</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI308</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be treated with IBI308</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high-dose recombinant interferon a-2B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be treated with recombinant interferon a-2B</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI310+IBI308</intervention_name>
    <description>In this group, subjects will be given IBI310 3mg/kg IV Q3W in combination with IBI308 200mg IV Q3W for 4 cycles, then follow up a maintenance therapy performed with IBI310 3mg/kg IV Q12W in combination with IBI308 200mg IV Q3W until disease progression or loss of clinical benefit.</description>
    <arm_group_label>IBI310 + IBI308</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI308</intervention_name>
    <description>In this group, subjects will be given IBI308 200mg IV Q3W until disease progression or loss of clinical benefit</description>
    <arm_group_label>IBI308</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High-dose recombinant interferon a-2B</intervention_name>
    <description>In this group, subjects will be given 15*10^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5 weekly for 4 weeks.Then 9*10^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks</description>
    <arm_group_label>high-dose recombinant interferon a-2B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and Female aged between 18 and 75 years are eligible;

          2. It was confirmed by histopathology that it was a acral melanoma;

          3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;

          4. Complete excision of primary focal area, surgical incision; All patients must have
             disease-free status documented by a complete physical examination and imaging studies
             prior to registration;

          5. No adjuvant therapy was received;

          6. No treatment contraindication, peripheral blood, normal liver, kidney function and
             electrocardiogram are normal; ANC≥1.5×10^9/L,PLT≥90×10^9/L,Hgb≥90.g/dL; serum urea
             nitrogen, cr≤1.5*ULN; ALT,ASTI≤2.5*ULN,

          7. Female subjects of childbearing age or male subjects of women of childbearing age need
             effective contraception during the entire treatment period and 6 months after the
             treatment period

        Exclusion Criteria：

          1. Mucosal-derived melanoma, uveal melanoma.

          2. Previous exposure to any anti-CTLA-4, anti-PD-1, anti-PD-L1 / 2 antibody or
             interferon.

          3. Hyperthyroidism or hypothyroidism. Note: Subjects who are stable after hormone
             replacement therapy can be enrolled.

          4. Participate in another clinical study at the same time.

          5. Have received any research drug within 4 weeks before the first dose of study
             treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>xiaomei shi</last_name>
    <phone>18151104552</phone>
    <email>xiaomei.shi@innoventbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing cancer hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jun guo</last_name>
      <phone>010-88196391</phone>
      <email>guoj307@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

